全文获取类型
收费全文 | 284篇 |
免费 | 21篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 31篇 |
妇产科学 | 2篇 |
基础医学 | 33篇 |
口腔科学 | 1篇 |
临床医学 | 13篇 |
内科学 | 50篇 |
皮肤病学 | 1篇 |
神经病学 | 21篇 |
特种医学 | 34篇 |
外科学 | 16篇 |
综合类 | 9篇 |
预防医学 | 27篇 |
眼科学 | 13篇 |
药学 | 26篇 |
肿瘤学 | 27篇 |
出版年
2022年 | 4篇 |
2021年 | 5篇 |
2020年 | 7篇 |
2018年 | 6篇 |
2017年 | 3篇 |
2016年 | 5篇 |
2014年 | 14篇 |
2013年 | 8篇 |
2012年 | 11篇 |
2011年 | 9篇 |
2010年 | 9篇 |
2009年 | 8篇 |
2008年 | 7篇 |
2007年 | 10篇 |
2006年 | 6篇 |
2005年 | 5篇 |
2004年 | 6篇 |
2003年 | 6篇 |
2002年 | 10篇 |
2001年 | 9篇 |
2000年 | 2篇 |
1999年 | 10篇 |
1998年 | 11篇 |
1997年 | 7篇 |
1996年 | 5篇 |
1995年 | 10篇 |
1994年 | 11篇 |
1993年 | 10篇 |
1992年 | 5篇 |
1991年 | 4篇 |
1990年 | 2篇 |
1989年 | 5篇 |
1987年 | 4篇 |
1986年 | 3篇 |
1985年 | 2篇 |
1984年 | 4篇 |
1983年 | 2篇 |
1982年 | 3篇 |
1981年 | 4篇 |
1980年 | 6篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1976年 | 8篇 |
1975年 | 4篇 |
1974年 | 6篇 |
1973年 | 3篇 |
1972年 | 2篇 |
1967年 | 2篇 |
1937年 | 2篇 |
排序方式: 共有305条查询结果,搜索用时 328 毫秒
1.
2.
Genotype-phenotype correlation for nucleotide substitutions in the IgII- IgIII linker of FGFR2 总被引:6,自引:3,他引:3
3.
C Morland J Michael D Adu T Kizaki A J Howie A Morgan N A Staines 《Clinical and experimental immunology》1991,83(1):126-132
The effect of the administration of a xenogeneic anti-idiotype antibody (anti-Id33) to a cross-reactive idiotype (Id33) present on anti-dsDNA antibody was examined in 6-week-old (NZB/NZW) F1 (BWF1) female mice. The administration of anti-Id33 led to a transient reduction in immunoglobulins expressing Id33, followed by a rise at 30 and 34 weeks that was significantly higher than in untreated mice (P less than 0.05). Likewise, anti-dsDNA antibody levels were significantly higher at 10 and 18 weeks than in untreated mice (P less than 0.01). No differences were seen in survival to 40 weeks, proteinuria or the severity of glomerulonephritis. Concurrent administration of cyclosporin A (CyA) with anti-Id33 markedly ameliorated glomerular injury and proteinuria and improved survival. By contrast, glomerular injury, proteinuria and survival were worse in mice treated with cyclophosphamide plus anti-Id33, compared with untreated mice. Neither CyA nor cyclophosphamide treatment, when given with anti-Id33 altered serum levels of anti-dsDNA, anti-ssDNA or Id33+ immunoglobin, compared with untreated mice. The different effects of CyA and cyclophosphamide on T lymphocytes and their discrepant effects on glomerular injury when given with anti-Id33 in this model lead us to postulate a role for T lymphocytes in the glomerular injury of BWF1 lupus. 相似文献
4.
Reorganization of human cortical maps caused by inherited photoreceptor abnormalities 总被引:3,自引:0,他引:3
We describe a compelling demonstration of large-scale developmental reorganization in the human visual pathways. The developmental reorganization was observed in rod monochromats, a rare group of congenitally colorblind individuals who virtually lack cone photoreceptor function. Normal controls had a cortical region, spanning several square centimeters, that responded to signals initiated in the all-cone foveola but was inactive under rod viewing conditions; in rod monochromats this cortical region responded powerfully to rod-initiated signals. The measurements trace a causal pathway that begins with a genetic anomaly that directly influences sensory cells and ultimately results in a substantial central reorganization. 相似文献
5.
L Ozzello CM De Rosa EW Blank K Cantell RL Ceriani DV Habif Sr 《Breast cancer research and treatment》1993,25(3):265-276
Summary An immunoconjugate composed of natural interferon (nIFN) bound in a noncleavable fashion to a monoclonal antibody (MoAb) recognizing a breast epithelial membrane mucin (Mc5) was used to treat xenografts of a human mammary carcinoma cell line (MCF-7) growing in nude mice. The immunoconjugate (nIFN/Mc5) was administered as 20 intralesional (i.l.) injections to 1 of 2 xenografts in each animal. It was found that nIFN/Mc5 produced a significant enhancement of the growth inhibitory actions of nIFN on the injected tumors. Further enhancement was obtained when nIFN or nIFN together with Mc5 (at a dose 10 times larger than that present in nIFN/Mc5) were added to the immunoconjugate. Biodistribution experiments showed that the uptake of125I-nIFN/Mc5 by the tumors was greater and its elimination slower than for125I-nIFN alone or conjugated to irrelevant mouse IgG1. In addition, the immunoconjugate up-regulated the antigenic expression of a breast epithelial membrane mucin by the carcinoma cells, an up-regulation which was not significantly different from that produced by nIFN alone. The contralateral noninjected tumors exposed to systemic levels of the immunoconjugate showed an enhancement of antitumor effects, but to a lesser extent than the injected tumors. These findings suggest that the enhancement of the growth inhibitory action of the immunoconjugate was related to the specific binding of Mc5 which targeted the IFN to the carcinoma cells and impeded its elimination. It is likely that the targeting was favored by the IFN-mediated up-regulation of antigenic expression by the carcinoma cells, thereby producing a cascade of interrelated effects. The results of this study point out the feasibility and potential usefulness of IFN treatment by means of immunoconjugates as well as the worth of pursuing and improving this form of therapy. 相似文献
6.
Pellegrino ED Harvey JC Morland EW Wessell ML Curtin T 《Health progress (Saint Louis, Mo.)》1991,72(2):66-69
The availability and accessibility of healthcare to those unable to pay is deteriorating rapidly. One place this is clearly apparent is in our nation's capital, where extremes of poverty and wealth abound. In an effort to improve access to healthcare for the poor, homeless, and medically indigent in the Washington, DC, area, the Washington Archdiocese Health Care Network (AHCN) was formed in 1984 under the leadership of Card. James A. Hickey. The AHCN is a coordinating agency that refers people in need to physicians, physical therapy and rehabilitation services, and dentists who have agreed to volunteer their services to this vulnerable population. The formation, operation, and continuation of the AHCN are performed by five members of one steering committee on behalf of the hundreds of volunteers who make it work daily. 相似文献
7.
Informed consent, parental awareness, and reasons for participating in a randomised controlled study
M van Stuijvenberg MH Suur S de Vos GC Tjiang EW Steyerberg G Derksen-Lubsen HA Moll 《Archives of disease in childhood》1998,79(2):120-125
BACKGROUND: The informed consent procedure plays a central role in randomised controlled trials but has only been explored in a few studies on children. AIM: To assess the quality of the informed consent process in a paediatric setting. METHODS: A questionnaire was sent to parents who volunteered their child (230 children) for a randomised, double blind, placebo controlled trial of ibuprofen syrup to prevent recurrent febrile seizures. RESULTS: 181 (79%) parents responded. On average, 73% of parents were aware of the major study characteristics. A few had difficulty understanding the information provided. Major factors in parents granting approval were the contribution to clinical science (51%) and benefit to the child (32%). Sociodemographic status did not influence initial participation but west European origin of the father was associated with willingness to participate in future trials. 89% of participants felt positive about the informed consent procedure; however, 25% stated that they felt obliged to participate. Although their reasons for granting approval and their evaluation of the informed consent procedure did not differ, relatively more were hesitant about participating in future. Parents appreciated the investigator being on call 24 hours a day (38%) and the extra medical care and information provided (37%) as advantages of participation. Disadvantages were mainly the time consuming aspects and the work involved (23%). CONCLUSIONS: Parents' understanding of trial characteristics might be improved by designing less difficult informed consent forms and by the investigator giving extra attention and information to non-west European parents. Adequate measures should be taken to avoid parents feeling obliged to participate, rather than giving true informed consent. 相似文献
8.
E. J. Estlin L. Lashford S. Ablett L. Price R. Gowing A. Gholkar J. Kohler I. J. Lewis B. Morland C. R. Pinkerton M. C. Stevens M. Mott R. Stevens D. R. Newell D. Walker C. Dicks-Mireaux H. McDowell P. Reidenberg P. Statkevich A. Marco V. Batra M. Dugan A. D. Pearson 《British journal of cancer》1998,78(5):652-661
A phase I study of temozolomide administered orally once a day, on 5 consecutive days, between 500 and 1200 mg m(-2) per 28-day cycle was performed. Children were stratified according to prior craniospinal irradiation or nitrosourea therapy. Sixteen of 20 patients who had not received prior craniospinal irradiation or nitrosourea therapy were evaluable. Myelosuppression was dose limiting, with Common Toxicity Criteria (CTC) grade 4 thrombocytopenia occurring in one of six patients receiving 1000 mg m(-2) per cycle, and two of four patients treated at 1200 mg m(-2) per cycle. Therefore, the maximum-tolerated dose (MTD) was 1000 mg m(-2) per cycle. The MTD was not defined for children with prior craniospinal irradiation because of poor recruitment. Plasma pharmacokinetic analyses showed temozolomide to be rapidly absorbed and eliminated, with linear increases in peak plasma concentrations and systemic exposure with increasing dose. Responses (CR and PR) were seen in two out of five patients with high-grade astrocytomas, and one patient had stable disease. One of ten patients with diffuse intrinsic brain stem glioma achieved a long-term partial response, and a further two patients had stable disease. Therefore, the dose recommended for phase II studies in patients who have not received prior craniospinal irradiation or nitrosoureas is 1000 mg m(-2) per cycle. Further evaluation in diffuse intrinsic brain stem gliomas and other high-grade astrocytomas is warranted. 相似文献
9.
Leslie A. Morland Allison R. Love Margaret‐Anne Mackintosh Carolyn J. Greene Craig S. Rosen 《Clinical psychology》2012,19(3):305-322
Anger is a common symptom among military populations with posttraumatic stress disorder (PTSD); yet, anger treatment has received relatively little attention in the literature. This discrepancy is surprising given that excessive anger is a key predictor of treatment outcome in PTSD. This study seeks to (a) build a case for the importance of a more explicit approach to understanding and treating anger in our military and veteran populations, (b) summarize the current literature base on treatment factors and treatment outcomes for treating anger and related symptoms among veterans, and (c) offer clinical and research implications and recommendations based on current findings and on the expertise of the authors in completing a large‐scale study of anger treatment with veterans. 相似文献
10.
Craig Gerrand Nick Athanasou Bernadette Brennan Robert Grimer Ian Judson Bruce Morland David Peake Beatrice Seddon Jeremy Whelan On behalf of the British Sarcoma Group 《Clinical sarcoma research》2016,6(1):7
This document is an update of the British Sarcoma Group guidelines published in 2010. The aim is to provide a reference standard for the clinical care of patients in the UK with bone sarcomas. Recent recommendations by the European Society of Medical Oncology, The National Comprehensive Cancer Network and The National Institute for Health and Care Excellence have been incorporated, and the literature since 2010 reviewed. The standards represent a consensus amongst British Sarcoma Group members in 2015. It is acknowledged that these guidelines will need further updates as care evolves. The key recommendations are that bone pain or a palpable mass should always lead to further investigation and that patients with clinico-radiological findings suggestive of a primary bone tumour at any site in the skeleton should be referred to a specialist centre and managed by a fully accredited bone sarcoma multidisciplinary team. Treatment recommendations are provided for the major tumour types and for localised, metastatic and recurrent disease. Follow up schedules are suggested. 相似文献